Immunitas Therapeutics

Immunitas Therapeutics company information, Employees & Contact Information

Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 and is in clinical trials for patients with refractory tumors across a variety of indications including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. Our second program is a novel therapeutic for the treatment of autoimmune disease that builds on our specialized foundational knowledge of the CD161-CLEC2D pathway.

Company Details

Employees
30
Founded
-
Address
21 Hickory Dr, Waltham,massachusetts 02451,united States
Email
in****@****stx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Waltham, Massachusetts
Looking for a particular Immunitas Therapeutics employee's phone or email?

Immunitas Therapeutics Questions

News

Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity - PR Newswire

Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity PR Newswire

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009 - PR Newswire

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009 PR Newswire

Immunitas Therapeutics Appoints Annalisa D'Andrea, Ph.D., as Chief Scientific Officer - PR Newswire

Immunitas Therapeutics Appoints Annalisa D'Andrea, Ph.D., as Chief Scientific Officer PR Newswire

Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting - PR Newswire

Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting PR Newswire

Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer - PR Newswire

Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer PR Newswire

Immunitas Therapeutics Announces Appointment of James Wooldridge as Chief Medical Officer and Upcoming Presentation at ASH 2023 Annual Meeting - PR Newswire

Immunitas Therapeutics Announces Appointment of James Wooldridge as Chief Medical Officer and Upcoming Presentation at ASH 2023 Annual Meeting PR Newswire

Immunitas Therapeutics Names Amanda Wagner as CEO - PR Newswire

Immunitas Therapeutics Names Amanda Wagner as CEO PR Newswire

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases - PR Newswire

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases PR Newswire

Immunitas Therapeutics Appoints Seng-Lai 'Thomas' Tan, Ph.D. as Chief Scientific Officer - PR Newswire

Immunitas Therapeutics Appoints Seng-Lai 'Thomas' Tan, Ph.D. as Chief Scientific Officer PR Newswire

Top Immunitas Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant